The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Dec 12 () - The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector ...

Ozempic has been approved for type-2 diabetes, while Novo Nordisk’s other global blockbuster Wegovy is targeted at obesity.

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...

Lilly's next-generation obesity shot is starting to look like the company's most powerful swing yet in a market investors ...

The latest results will help cement Lilly's dominance in the obesity market that's expected to hit $100 billion by 2030.

Shortly after, Novo Nordisk's CEO Mike Doustdar signaled the company is "all in" on the forthcoming launch of oral semaglutide, emphasizing robust supply readiness ahead of the anticipated year-end ...

Novo Nordisk › Once a fast-growing pharmaceutical giant, Novo Nordisk (NYSE: NVO) has felt the effects of gravity over the past 18 months. The company's shares are down by more than 60% since early ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

Once a celebrated leader in the pharmaceutical sector, Novo Nordisk is now engaged in a fierce battle for investor confidence ...

Novo Nordisk A/S is planning a large study of its next-generation obesity shot CagriSema in children, a sign the drugmaker is ...

Wall Street staged a cautious rebound, with major stock indexes edging mildly higher despite a rally in cryptocurrencies that ...